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INTRODUCTION: 
Osteoarthritis (OA) is one of the most common form of 
joint disease in humans and is a leading cause of 
musculoskeletal d isability in elderly patients .
1
 The World 
Health Organization (WHO) figures of world wide 
estimates are that 9.6% of men and 18% of women aged 
more than 60 years have symptomatic OA .
2
 
Combination of orally administered Non-steroidal anti-
inflammatory drugs and non pharmacolog ical intervention 
play an important role in the symptomatic management of 
osteoarthritis. The ideal agent should have good efficacy 
and low propensity to cause adverse effects. 
While NSAIDs are effective in the management of pain 
and inflammat ion in a large number of conditions 
including osteoarthritis, it is now well established that they 
are associated with development of upper gastrointestinal 
damage, including mucosal erosions, ulcers and life 
threatening conditions like perforation and hemorrhage. 
This led to the development of cyclo-oxygenase-2 
inhibitors. The potential advantage of COX-2 inhibitor is 
that they have fewer adverse effects on the gastrointestinal 
tract as a result of having less inhibitory effect on the 
gastro-protective prostanoids produced by COX-1 enzyme 
in the gastrointestinal tract. This advantage of COX-2 
selective NSAIDs has been demonstrated in many trials.
3-5 
However the cardiovascular safety of these drugs was 
found to be controversial. Three independent randomized  
trials and a cumulative meta-analysis confirmed excess 
cardiovascular risk as well as serious skin reactions were 
also seen with rofecoxib and valdecoxib. 
6, 7
   
Diclofenac is an already established Non-steroidal anti-
inflammatory drug with analgesic and antipyretic 
properties. Diclofenac inhibits cyclo-oxygenase activity 
with reduction in the tissue production of prostaglandins. It 
reduces joint swelling and relieves pain so is used in the 
treatment of rheumatoid arthritis and osteoarthritis. But 
studies on Diclofenac has shown increased incidence of 
adverse effects like abdominal pain, dyspepsia, diarrhoea, 
heartburn and GI u lcer. 
Aceclofenac is an effective analgesic and anti-
inflammatory agent; through these properties it provides 
greater symptomat ic relief in a variety of painful 
conditions.
8
 It has also shown to exert effects on a variety 
of mediators of inflammation. The drug inhibits synthesis 
of inflammatory cytokines like interleukin (IL)-1β and 
tumor necrosis factor (TNF) and inhibits prostaglandin E2 
(PGE2) production. The mode of action of Aceclofenac 
has been recently clarified in that the compound was 
shown to elicit preferential inh ibition of COX-2 as a result 
of limited but sustained biotransformation to Diclofenac. 
9
   
The present study was carried out to evaluate the efficacy 
and Safety of Aceclofenac for the treatment of 
osteoarthritis compared to Diclofenac. 
MATERIALS AND METHODS: 
Subjects: 
The study was conducted on 140 patients aged 40-60 years 
with a history, symptoms and signs of osteoarthritis, 
radiologically d iagnosed with osteoarthritis of knee, 
minimum Western Ontario MacMaster (WOMAC) Index 
of 40, Visual Analogue scale (VAS) score of 4mm with 
normal haematology, renal function test and liver function 
test values were recruited from the Orthopaedic outpatient 
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department of Prathima Institute of Medical Sciences, 
Karimnagar, AP, India. Patients suffering from other 
rheumatic disease, with significant concomitant illness 
(e.g. bleeding tendencies, cirrhosis, esophageal varices, 
hypersensitivity to NSAIDs, peptic ulcers and duodenal 
ulcers), pregnant women, lactating mothers, patient’s who 
would require concomitant therapy with drugs (e.g. 
warfarin, aspirin, corticosteroids, ticlopidine, antiepileptics 
and fluconazole)  and who have previously received 
Diclofenac and or Aceclofenac for treatment of 
osteoarthritis were  excluded from the study. 
Study design: 
The present study is a randomized, single blinded, parallel 
group comparative clin ical study between Diclofenac and 
Aceclofenac in osteoarthritis of knee. The study was 
approved by Institute Ethical Committee and procedures 
followed in this study are in accordance with the ethical 
standards laid down by ICMR’s Ethical guidelines for 
biomedical research on human subjects (2006). A written 
informed consent was taken from all the patients included 
in the trial after explaining the patient’s diagnosis, the 
nature and purpose of a proposed treatment, the risks and 
benefits of a proposed treatment (Diclofenac/ Aceclofenac) 
and alternative treatment (Cort icosteroids). After 
randomizat ion by computer generated random numbers 
(done online: www.randomization.com), 140 patients who 
participated in the study were div ided into two groups; 70 
patients were assigned to receive Diclofenac 75mg twice 
daily and 70 patients received Aceclofenac 100mg twice 
daily for a period of 8 weeks. During the screening visit, 
informat ion on their demographic characteristics, medical 
history and previous current medications was collected. A  
thorough physical examination and baseline laboratory 
investigations were carried out. At 8 weeks follow up, 
physical examination and baseline investigation were 
repeated and all post drug symptoms were recorded  
Efficacy measures:  
WOMAC Osteoarthritis Index was administered at both 
clin ical v isits, evaluating the following domains: pain, 
stiffness and difficu lty performing daily activities using a 
battery of 24 questions. Every question was rated from 
‘none (0)’, ‘mild (1)’, ‘moderate (2)’, ‘severe (3)’ and 
‘very severe (4)’.  
Visual Analog Scale bypasses the cognitive level of brain 
and gives a true representation of pain. Symptom score for 
pain on 0-10mm VAS was calculated for weight bearing, 
pain at rest and active movement  
The patient was made to walk a distance of 100 feet and 
time taken was noted in seconds. The patient rated the 
overall response of his or her OA to study medications on 
a 0-4 Likert scale (‘none’, ‘Poor’, ‘moderate’, ‘good’, and 
‘excellent’). The investigator rated the overall assessment 
of disease status on a 0-4 Likert scale (‘very poor’, ‘poor’, 
‘moderate’, ‘well’ and ‘very well’). The investigator rated 
the response of the patient’s OA to study medicat ion on a 
0-4 Likert scale (‘none’, ‘Poor’, ‘moderate’, ‘good’, and 
‘excellent’). Assessment of joint tenderness on 0-3 scale 
(‘no pain ’, ‘pain’, ‘pain and wincing’ and ‘withdrawal’). 
Safety measures: 
Safety was assessed on the basis of the adverse events 
reported, or by comparing the baseline symptoms with 
post-drug symptoms, or changes in vital signs, and 
physical examination findings recorded before and after 
the end of treatment. All reported adverse drug reactions 
were graded according to Common Toxicity Criteria 
(CTC) and compared between the groups. 
Statistical analysis: 
Statistical Package for Social Sciences (SPSS) version 
17.0 software was used for analyzing results . Statistical 
test conducted were Paired t-test, Un-paired t-test, Pearson 
chi-square test and Fisher’s exact test. Interval data have 
been expressed as Mean ± SD. P value < 0.05 was 
considered statistically significant.   
RES ULTS:       
In our study the two groups were homogenous with respect 
to baseline demographic data. At follow-up, 22 were lost 
and total 118 patients (60 in Aceclofenac group and 58 in  
Diclofenac group) completed the study. Among 140 
patients, 86 patients (61.42%) were female and 54 patients 
(38.58%) were male. The mean age was 52.80 ± 4.55 years 
in Diclofenac group and 53.61 ± 5.64 years in Aceclofenac 
group. 
 
Table 1: Change in WOMAC Osteoarthritis Index scores in study groups  
 
 
Variable 
 
Diclofenac group Aceclofenac group Difference 
b/w  groups 
at 2
nd
 visit  
 
Visit P value    
$ 
Visit P value  
$ 
1
st
 2
nd
 1
st
 2
nd
 
Pain questionnaire 
scoring 
 
12.3 ± 3.13 
 
8.76 ± 1.09 
 
<0.0001 
 
12.0 ± 1.08 
 
7.60 ±1.18 
 
<0.0001 
 
<0.0001 
Stiffness questionnaire 
scoring 
 
4.21 ± 0.58 
 
3.26 ± 0.76 
 
<0.0001 
 
4.17 ± 0.61 
 
2.73 ± 0.75 
 
<0.0001 
 
<0.0001 
Difficulty performing 
daily activ ities 
questionnaire scoring 
 
 
39.91 ± 2.14 
 
 
30.66 ± 1.78 
 
 
<0.0001 
 
 
40.67±2.17 
 
 
29.03 ± 2.06 
 
 
<0.0001 
 
 
<0.0001 
WOMAC score 
(overall) 
56.48 ± 3.59 42.67 ± 1.99 <0.0001 56.83 ± 2.31 38.0 ± 2.29 <0.0001 <0.0001 
Data are in Mean ± SD, $=Paired t-test,= Unpaired t-test 
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Figure 1: Participant flow through the study 
Table 2: Change in Visual Analogue scale scores for pain in study groups.  
 
 
Variable 
 
Diclofenac group Aceclofenac group Difference 
b/w groups 
at 2
nd
 visit 
 
Visit P value    
$ 
Visit P value  
 $ 1
st
 2
nd
 1
st
 2
nd
 
During weight bearing  5.29 ± 0.95 2.88 ± 1.09 <0.0001 5.30 ± 0.83 2.77 ± 0.92 <0.0001 0.547 
At rest 4.72 ± 0.93 2.71 ± 1.02 <0.0001 4.83 ± 1.02 2.38 ± 0.84 <0.0001 0.064 
During active 
movement 
5.40 ± 0.93 3.65 ± 1.25 <0.0001 5.20 ±0.86 2.87 ± 1.21 <0.0001 0.207 
Data are in Mean ± SD, $=Paired t-test, = Unpaired t-test 
The changes in WOMAC osteoarthritis index scores, joint 
tenderness score, investigators assessment of disease status 
score and response to therapy and patient’s response to 
drug in both Diclofenac and Aceclofenac groups were 
statistically significant by paired t-test and when the same 
parameters were compared at 2
nd
 visit between Diclo fenac 
and Aceclofenac groups by unpaired t-test, there was 
significant difference between the groups. Both 
Aceclofenac and Diclofenac were equally  effect ive in  
significantly reducing VAS pain score during weight 
bearing, at rest and during active movement, and also time 
taken to walk 100 feet distance. In our study all the 
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reported side effects were of grade 1 (mild), according to 
CTC grading of adverse drug reactions. No clinically  
significant post-treatment changes were observed in 
haematology, renal function test and liver function test in 
any of the patients. The overall incidence of adverse 
effects was 29.4% in Diclofenac group and 11.7% in  
Aceclofenac group. To compare the incidence of adverse 
effects of two groups Fischer’s Exact test was done and it 
was found to be statistically significant in Diclo fenac 
group(p=0.02).  
 
Table 3: Change in efficacy measures in study groups.  
Data are in Mean ± SD, $=Paired t-test, = Unpaired t-test 
Table 4: Assessment of res ponse to drug 
Variable  Diclofenac group Aceclofenac group    P value 
By Investigator 2.36 ± 1.07 2.75 ± 0.93 0.038 
By Pat ient 2.19 ± 0.60 2.47 ± 0.70 0.024 
Data are in Mean ± SD, = Unpaired t-test 
DISCUSS ION: 
Treating the symptoms of osteoarthritis and ensuring a 
decent quality of life to the patients is challenging to the 
physician. Increasing understanding of the 
pathophysiological mechanism in the last few decades 
have revealed the use of different NSAIDS in the treatment 
of osteoarthritis. 
 In our study improvement was seen in all three domains 
and overall WOMAC osteoarthritis index with both the 
drugs. But the improvement with Aceclofenac was found 
to be better in comparison to Diclofenac. The find ings of 
our study are similar to that of the previous studies done by 
Pareek A et al 2006.
10 
Both the drugs are almost equally 
effective in reducing pain score during weight bearing, at 
rest and on active movement by visual analogue scale. Our 
results are comparable with the  study done by Pareek A et 
al 2006 and Ward DE et al 1995.
10, 11 
In our study 
Aceclofenac is superior to Diclofenac in decreasing jo int 
tenderness score similar to  previous studies by Pareek A 
et al 2006 and Ward DE et al 1995.
10,11 
 Aceclofenac was 
better than Diclofenac in improving the disease and 
investigator response to therapy, which is supported by 
previous studies done by Ward DE et al 1995.
11 
Patient 
response to Aceclofenac was better than Diclofenac which  
is supported by  previous studies done by  Ward DE et al 
1995, Wassif et al 1992, Accardo S et al 1995.
11-13
 The 
superiority of Aceclofenac in our study may be attributed 
to its stimulatory effect on cartilage matrix synthesis by 
inhibit ing IL-β. There is evidence that Aceclofenac 
stimulates the synthesis of IL-1 receptor antagonist in 
human articu lar chondrocyte subjected to inflammatory  
stimuli
14
 and that 4-hydroxyaceclofenac has 
chondroprotective properties attributed to suppression of 
IL-1β mediated promatrix metalloproteinase production 
and proteoglycan release.
15,16 
In vitro data has shown that, 
there is stimulation of glycosaminoglycan synthesis in 
human osteoarthritic cartilage by Aceclofenac. The anti-
inflammatory effects of Aceclofenac have been shown due 
to inhibition of various mediators like IL-1β, IL-6 and 
tumor necrosis factor in  human osteoarthritic synovial cells 
and human articu lar chondrocytes, inhibition of PGE2 via 
cyclooxygenase inhibition (COX-1 & COX-2) after 
intracellular metabolism to 4 hydroxy-aceclofenac and 
Diclofenac in human rheumatoid synovial cells and other 
inflammatory cells, inhibit ion of React ive oxygen species , 
expression of cell adhesion molecules  has also been shown 
in human neutrophils. The overall incidence of adverse 
effects in our study was 29.4% in Diclo fenac and 11.7% in  
Aceclofenac group. Aceclofenac was well tolerated than 
Diclofenac in terms of epigastric discomfort, dyspepsia 
and abdominal pain. This is supported by previous study 
done by Pareek A et al 2006, Ward DE et al 1995, Wassif 
et al 1992 and Accardo S et al 1995. 
10,11,12, 13
 
CONCLUS ION: 
Analysis of results of all the parameters of safety and 
efficacy explores the probable superiority of Aceclofenac 
over Diclofenac in osteoarthritis. Because single blinding 
was a limitation, the findings of this study can be 
confirmed by mult icentric, randomized, double blinded 
large population studies. 
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Variable 
 
Diclofenac group Aceclofenac group Difference 
b/w groups 
at 2
nd
 visit 
 
Visit P value    
$ 
Visit P value  
$ 
1
st
 2
nd
 1
st
 2
nd
 
Time taken to walk 
100ft  
 
102 ± 3.59 
 
84.93 ± 9.02 
 
<0.0001 
 
101.45 ± 11.65 
 
82.88 ± 9.35 
 
<0.0001 
 
 0.230 
Joint tenderness 
score 
 
1.48 ± 1.06 
 
0.81± 0.57 
 
<0.0001 
 
1.58 ± 0.94 
 
0.53 ± 0.50 
 
<0.0001 
 
 0.006 
Disease status score 2.36 ± 0.66 2.52 ± 0.62 0.028 2.20 ± 0.65 2.82 ± 0.62 <0.0001 0.011 
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